{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:59:46Z","timestamp":1780603186478,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,29]]},"DOI":"10.7759\/cureus.65708","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T05:28:04Z","timestamp":1722317284000},"source":"Crossref","is-referenced-by-count":2,"title":["Dorzagliatin: A Breakthrough Glucokinase Activator Coming on Board to Treat Diabetes Mellitus"],"prefix":"10.7759","author":[{"given":"Ramya","family":"Raju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indumathi","family":"Prabath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indumathi","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathyanarayanan","family":"Varadarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399819666230413094200","article-title":"Prevalence of diabetes in India: a review of IDF Diabetes Atlas 10th Edition","volume":"20","author":"Kumar A","year":"2024","unstructured":"Kumar A, Gangwar R, Zargar AA, Kumar R, Sharma A. Prevalence of diabetes in India: a review of IDF Diabetes Atlas 10th Edition. Curr Diabetes Rev. 2024, 20:e130423215752. 10.2174\/1573399819666230413094200","journal-title":"Curr Diabetes Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.04.044","article-title":"Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis","volume":"14","author":"Kumar A","year":"2020","unstructured":"Kumar A, Arora A, Sharma P, et al.. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr. 2020, 14:535-45. 10.1016\/j.dsx.2020.04.044","journal-title":"Diabetes Metab Syndr"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010571","article-title":"New-generation glucokinase activators: potential game-changers in type 2 diabetes treatment","volume":"25","author":"Haddad D","year":"2024","unstructured":"Haddad D, Dsouza VS, Al-Mulla F, Al Madhoun A. New-generation glucokinase activators: potential game-changers in type 2 diabetes treatment. Int J Mol Sci. 2024, 25:571. 10.3390\/ijms25010571","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1117-6","article-title":"Minutes of the 43rd general assembly of the European association for the study of diabetes","volume":"51","year":"2008","unstructured":"Minutes of the 43rd general assembly of the European association for the study of diabetes. Diabetologia. 2008, 51.1-588. 10.1007\/s00125-008-1117-6","journal-title":"Diabetologia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/db22-0708","article-title":"Dorzagliatin, a dual-acting glucokinase activator, increases insulin secretion and glucose sensitivity in glucokinase maturity-onset diabetes of the young and recent-onset type 2 diabetes","volume":"72","author":"Chow E","year":"2023","unstructured":"Chow E, Wang K, Lim CK, et al.. Dorzagliatin, a dual-acting glucokinase activator, increases insulin secretion and glucose sensitivity in glucokinase maturity-onset diabetes of the young and recent-onset type 2 diabetes. Diabetes. 2023, 72:299-308. 10.2337\/db22-0708","journal-title":"Diabetes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12294","article-title":"Present status of clinical deployment of glucokinase activators","volume":"6","author":"Nakamura A","year":"2015","unstructured":"Nakamura A, Terauchi Y. Present status of clinical deployment of glucokinase activators. J Diabetes Investig. 2015, 6:124-32. 10.1111\/jdi.12294","journal-title":"J Diabetes Investig"},{"key":"ref7","article-title":"Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2","volume":"75","author":"Li W","year":"2020","unstructured":"Li W, Zhang X, Sun Y, Liu Z. Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2. Pharmazie. 2020, 75:230-5.","journal-title":"Pharmazie"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2019.01.011","article-title":"Molecular and cellular regulation of human glucokinase","volume":"663","author":"Sternisha SM","year":"2019","unstructured":"Sternisha SM, Miller BG. Molecular and cellular regulation of human glucokinase. Arch Biochem Biophys. 2019, 663:199-213. 10.1016\/j.abb.2019.01.011","journal-title":"Arch Biochem Biophys"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01278-z","article-title":"Glucokinase activators for type 2 diabetes: challenges and future developments","volume":"80","author":"Toulis KA","year":"2020","unstructured":"Toulis KA, Nirantharakumar K, Pourzitaki C, Barnett AH, Tahrani AA. Glucokinase activators for type 2 diabetes: challenges and future developments. Drugs. 2020, 80:467-75. 10.1007\/s40265-020-01278-z","journal-title":"Drugs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-s236","article-title":"Glucokinase activators for diabetes therapy: May 2010 status report","volume":"34","author":"Matschinsky FM","year":"2011","unstructured":"Matschinsky FM, Zelent B, Doliba N, et al.. Glucokinase activators for diabetes therapy: May 2010 status report. Diabetes Care. 2011, 34:S236-43. 10.2337\/dc11-s236","journal-title":"Diabetes Care"},{"key":"ref11","unstructured":"Hua Medicine announces acceptance of a new drug application for dorzagliatin in China - First glucokinase activator (GKA) globally. (2021). Accessed. June 13, 2024: https:\/\/www.huamedicine.com\/En\/news-205."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/BF01862955","article-title":"Beitrag zur kenntnis der regulation der insulinproduktion","volume":"125","author":"Grafe E","year":"1927","unstructured":"Grafe E, Meythaler F. Beitrag zur kenntnis der regulation der insulinproduktion. Archiv f experiment Pathol u Pharmakol. 1927, 125:181-92. 10.1007\/BF01862955","journal-title":"Archiv f experiment Pathol u Pharmakol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.00148","article-title":"The central role of glucokinase in glucose homeostasis: a perspective 50 years after demonstrating the presence of the enzyme in islets of Langerhans","volume":"10","author":"Matschinsky FM","year":"2019","unstructured":"Matschinsky FM, Wilson DF. The central role of glucokinase in glucose homeostasis: a perspective 50 years after demonstrating the presence of the enzyme in islets of Langerhans. Front Physiol. 2019, 10:148. 10.3389\/fphys.2019.00148","journal-title":"Front Physiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1963.205.4.638","article-title":"Effects of carbohydrates on secretion of insulin from isolated rat pancreas","volume":"205","author":"Grodsky GM","year":"1963","unstructured":"Grodsky GM, Batts AA, Bennett LL, Vcella C, Mcwilliams NB, Smith DF. Effects of carbohydrates on secretion of insulin from isolated rat pancreas. Am J Physiol. 1963, 205:638-44. 10.1152\/ajplegacy.1963.205.4.638","journal-title":"Am J Physiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(67)90171-0","article-title":"Effect of pulse administration of glucose or glucagon on insulin secretion in vitro","volume":"16","author":"Grodsky GM","year":"1967","unstructured":"Grodsky GM, Bennett LL, Smith DF, Schmid FG. Effect of pulse administration of glucose or glucagon on insulin secretion in vitro. Metabolism. 1967, 16:222-33. 10.1016\/0026-0495(67)90171-0","journal-title":"Metabolism"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)93432-0","article-title":"Metabolism of glucose in the islets of Langerhans","volume":"243","author":"Matschinsky FM","year":"1968","unstructured":"Matschinsky FM, Ellerman JE. Metabolism of glucose in the islets of Langerhans. J Biol Chem. 1968, 243:2730-6. 10.1016\/S0021-9258(18)93432-0","journal-title":"J Biol Chem"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1970.sp009207","article-title":"Glucose-induced electrical activity in pancreatic islet cells","volume":"210","author":"Dean PM","year":"1970","unstructured":"Dean PM, Matthews EK. Glucose-induced electrical activity in pancreatic islet cells. J Physiol. 1970, 210:255-64. 10.1113\/jphysiol.1970.sp009207","journal-title":"J Physiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/BF00586918","article-title":"Membrane potential of beta-cells in pancreatic islets","volume":"351","author":"Meissner HP","year":"1974","unstructured":"Meissner HP, Schmelz H. Membrane potential of beta-cells in pancreatic islets. Pflugers Arch. 1974, 351:195-206. 10.1007\/BF00586918","journal-title":"Pflugers Arch"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/312446a0","article-title":"Glucose induces closure of single potassium channels in isolated rat pancreatic \u03b2-cells","volume":"312","author":"Ashcroft FM","year":"1984","unstructured":"Ashcroft FM, Harrison DE, Ashcroft SJ. Glucose induces closure of single potassium channels in isolated rat pancreatic \u03b2-cells. Nature. 1984, 312:446-8. 10.1038\/312446a0","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.24.12038","article-title":"Expression of yeast hexokinase in pancreatic beta cells of transgenic mice reduces blood glucose, enhances insulin secretion, and decreases diabetes","volume":"89","author":"Epstein PN","year":"1992","unstructured":"Epstein PN, Boschero AC, Atwater I, Cai X, Overbeek PA. Expression of yeast hexokinase in pancreatic beta cells of transgenic mice reduces blood glucose, enhances insulin secretion, and decreases diabetes. Proc Natl Acad Sci U S A. 1992, 89:12038-42. 10.1073\/pnas.89.24.12038","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.38.22085","article-title":"Inhibition of insulin receptor phosphorylation by PC-1 is not mediated by the hydrolysis of adenosine triphosphate or the generation of adenosine","volume":"270","author":"Grupe A","year":"1995","unstructured":"Grupe A, Alleman J, Goldfine ID, Sadick M, Stewart TA. Inhibition of insulin receptor phosphorylation by PC-1 is not mediated by the hydrolysis of adenosine triphosphate or the generation of adenosine. J Biol Chem. 1995, 270:22085-8. 10.1074\/jbc.270.38.22085","journal-title":"J Biol Chem"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90235-X","article-title":"Transgenic knockouts reveal a critical requirement for pancreatic \u03b2 cell glucokinase in maintaining glucose homeostasis","volume":"83","author":"Grupe A","year":"1995","unstructured":"Grupe A, Hultgren B, Ryan A, Ma YH, Bauer M, Stewart TA. Transgenic knockouts reveal a critical requirement for pancreatic \u03b2 cell glucokinase in maintaining glucose homeostasis. Cell. 1995, 83:69-78. 10.1016\/0092-8674(95)90235-X","journal-title":"Cell"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.51.30253","article-title":"Pancreatic \u03b2-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose","volume":"270","author":"Terauchi Y","year":"1995","unstructured":"Terauchi Y, Sakura H, Yasuda K, et al.. Pancreatic \u03b2-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J Biol Chem. 1995, 270:30253-6. 10.1074\/jbc.270.51.30253","journal-title":"J Biol Chem"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.36.22570","article-title":"Effects of increased glucokinase gene copy number on glucose homeostasis and hepatic glucose metabolism","volume":"272","author":"Niswender KD","year":"1997","unstructured":"Niswender KD, Shiota M, Postic C, Cherrington AD, Magnuson MA. Effects of increased glucokinase gene copy number on glucose homeostasis and hepatic glucose metabolism. J Biol Chem. 1997, 272:22570-5. 10.1074\/jbc.272.36.22570","journal-title":"J Biol Chem"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1126\/science.1084073","article-title":"Allosteric activators of glucokinase: potential role in diabetes therapy","volume":"301","author":"Grimsby J","year":"2003","unstructured":"Grimsby J, Sarabu R, Corbett WL, et al.. Allosteric activators of glucokinase: potential role in diabetes therapy. Science. 2003, 301:370-3. 10.1126\/science.1084073","journal-title":"Science"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13327","article-title":"The thermodynamic basis of glucose-stimulated insulin release: a model of the core mechanism","volume":"5","author":"Wilson DF","year":"2017","unstructured":"Wilson DF, Cember AT, Matschinsky FM. The thermodynamic basis of glucose-stimulated insulin release: a model of the core mechanism. Physiol Rep. 2017, 5:e13327. 10.14814\/phy2.13327","journal-title":"Physiol Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.01077.2017","article-title":"Glutamate dehydrogenase: role in regulating metabolism and insulin release in pancreatic \u03b2-cells","volume":"125","author":"Wilson DF","year":"2018","unstructured":"Wilson DF, Cember AT, Matschinsky FM. Glutamate dehydrogenase: role in regulating metabolism and insulin release in pancreatic \u03b2-cells. J Appl Physiol (1985). 2018, 125:419-28. 10.1152\/japplphysiol.01077.2017","journal-title":"J Appl Physiol (1985)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2021.2025362","article-title":"Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists","volume":"37","author":"Ren Y","year":"2022","unstructured":"Ren Y, Li L, Wan L, Huang Y, Cao S. Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists. J Enzyme Inhib Med Chem. 2022, 37:606-15. 10.1080\/14756366.2021.2025362","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.1826","article-title":"Analysis of the pancreatic \u03b2 cell in the mouse with targeted disruption of the pancreatic \u03b2 cell-specific glucokinase gene","volume":"229","author":"Aizawa T","year":"1996","unstructured":"Aizawa T, Asanuma N, Terauchi Y, et al.. Analysis of the pancreatic \u03b2 cell in the mouse with targeted disruption of the pancreatic \u03b2 cell-specific glucokinase gene. Biochem Biophys Res Commun. 1996, 229:460-5. 10.1006\/bbrc.1996.1826","journal-title":"Biochem Biophys Res Commun"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.10.10.8751724","article-title":"Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver","volume":"10","author":"Ferre T","year":"1996","unstructured":"Ferre T, Riu E, Bosch F, Valera A. Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver. FASEB J. 1996, 10:1213-8. 10.1096\/fasebj.10.10.8751724","journal-title":"FASEB J"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.3.622","article-title":"Glucokinase gene locus transgenic mice are resistant to the development of obesity-Induced type 2 diabetes","volume":"50","author":"Shiota M","year":"2001","unstructured":"Shiota M, Postic C, Fujimoto Y, et al.. Glucokinase gene locus transgenic mice are resistant to the development of obesity-Induced type 2 diabetes. Diabetes. 2001, 50:622-9. 10.2337\/diabetes.50.3.622","journal-title":"Diabetes"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S105021","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study","volume":"10","author":"Xu H","year":"2016","unstructured":"Xu H, Sheng L, Chen W, et al.. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study. Drug Des Devel Ther. 2016, 10:1619-26. 10.2147\/DDDT.S105021","journal-title":"Drug Des Devel Ther"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30105-0","article-title":"Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study","volume":"6","author":"Zhu D","year":"2018","unstructured":"Zhu D, Gan S, Liu Y, et al.. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diabetes Endocrinol. 2018, 6:627-36. 10.1016\/S2213-8587(18)30105-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-733611\/v1","article-title":"The SEED study of dorzagliatin in drug-na\u00efve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial","author":"Chen L","year":"2022","unstructured":"Chen L, Zhu D, Li X, et al.. The SEED study of dorzagliatin in drug-na\u00efve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial. Nat Med. 2022, 1-22. 10.21203\/rs.3.rs-733611\/v1","journal-title":"Nat Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15179","article-title":"Diabetes remission in drug-na\u00efve patients with type 2 diabetes after dorzagliatin treatment: a prospective cohort study","volume":"25","author":"Zeng J","year":"2023","unstructured":"Zeng J, Gan S, Mi N, et al.. Diabetes remission in drug-na\u00efve patients with type 2 diabetes after dorzagliatin treatment: a prospective cohort study. Diabetes Obes Metab. 2023, 25:2878-87. 10.1111\/dom.15179","journal-title":"Diabetes Obes Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-733332\/v1","article-title":"The DAWN study of dorzagliatin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial [PREPRINT]","author":"Chen L","year":"2021","unstructured":"Chen L, Yang W, Zhu D, et al.. The DAWN study of dorzagliatin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial [PREPRINT]. Research Square. 2021, 10.21203\/rs.3.rs-733332\/v1","journal-title":"Research Square"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13174","article-title":"Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator","volume":"15","author":"Miao J","year":"2022","unstructured":"Miao J, Fu P, Ren S, et al.. Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator. Clin Transl Sci. 2022, 15:548-57. 10.1111\/cts.13174","journal-title":"Clin Transl Sci"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1200","article-title":"Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes","volume":"34","author":"Meininger GE","year":"2011","unstructured":"Meininger GE, Scott R, Alba M, et al.. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care. 2011, 34:2560-6. 10.2337\/dc11-1200","journal-title":"Diabetes Care"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.7.2056","article-title":"Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons","volume":"51","author":"Dunn-Meynell AA","year":"2002","unstructured":"Dunn-Meynell AA, Routh VH, Kang L, Gaspers L, Levin BE. Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons. Diabetes. 2002, 51:2056-65. 10.2337\/diabetes.51.7.2056","journal-title":"Diabetes"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.02.003","article-title":"Hypoglycemia-activated GLUT2 neurons of the nucleus tractus solitarius stimulate vagal activity and glucagon secretion","volume":"19","author":"Lamy CM","year":"2014","unstructured":"Lamy CM, Sanno H, Labou\u00e8be G, Picard A, Magnan C, Chatton JY, Thorens B. Hypoglycemia-activated GLUT2 neurons of the nucleus tractus solitarius stimulate vagal activity and glucagon secretion. Cell Metab. 2014, 19:527-38. 10.1016\/j.cmet.2014.02.003","journal-title":"Cell Metab"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094035","article-title":"Dynamic localization of glucokinase and its regulatory protein in hypothalamic tanycytes","volume":"9","author":"Salgado M","year":"2014","unstructured":"Salgado M, Tarife\u00f1o-Saldivia E, Ordenes P, et al.. Dynamic localization of glucokinase and its regulatory protein in hypothalamic tanycytes. PLoS One. 2014, 9:e94035. 10.1371\/journal.pone.0094035","journal-title":"PLoS One"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2337\/db15-1514","article-title":"Sex-specific control of fat mass and counterregulation by hypothalamic glucokinase","volume":"65","author":"Steinbusch LK","year":"2016","unstructured":"Steinbusch LK, Picard A, Bonnet MS, Basco D, Labou\u00e8be G, Thorens B. Sex-specific control of fat mass and counterregulation by hypothalamic glucokinase. Diabetes. 2016, 65:2920-31. 10.2337\/db15-1514","journal-title":"Diabetes"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02612-z","article-title":"Cost-effectiveness of newer antidiabetic drugs as second-line treatment for type 2 diabetes: a systematic review","volume":"40","author":"Zhu J","year":"2023","unstructured":"Zhu J, Zhou Y, Li Q, Wang G. Cost-effectiveness of newer antidiabetic drugs as second-line treatment for type 2 diabetes: a systematic review. Adv Ther. 2023, 40:4216-35. 10.1007\/s12325-023-02612-z","journal-title":"Adv Ther"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12651","article-title":"Adherence to diabetes medication: a systematic review","volume":"32","author":"Krass I","year":"2015","unstructured":"Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: a systematic review. Diabet Med. 2015, 32:725-37. 10.1111\/dme.12651","journal-title":"Diabet Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/272009-dorzagliatin-a-breakthrough-glucokinase-activator-coming-on-board-to-treat-diabetes-mellitus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T05:28:08Z","timestamp":1722317288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/272009-dorzagliatin-a-breakthrough-glucokinase-activator-coming-on-board-to-treat-diabetes-mellitus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.65708","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,29]]}}}